Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M574Revenue $M15.5Net Margin (%)-197.1Z-Score10.7
Enterprise Value $M465EPS $-0.8Operating Margin %-136.9F-Score3
P/E(ttm))0Cash Flow Per Share $-0.8Pre-tax Margin (%)-197.1Higher ROA y-yN
Price/Book6.810-y EBITDA Growth Rate %0Quick Ratio5.7Cash flow > EarningsY
Price/Sales31.85-y EBITDA Growth Rate %-1.0Current Ratio5.7Lower Leverage y-yY
Price/Cash Flow0y-y EBITDA Growth Rate %0ROA % (ttm)-34.9Higher Current Ratio y-yY
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)-45.1Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M22.3ROI % (ttm)148Gross Margin Increase y-yN

Gurus Latest Trades with TKMR

Number of guru portfolios checked: 85. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
TKMRJean-Marie Eveillard 2013-06-30 Sold Out $4.28 - $5.05
($4.74)
$ 25.52438%Sold Out0
TKMRJean-Marie Eveillard 2013-03-31 Buy $4.35 - $5.44
($4.73)
$ 25.52440%New holding, 25000 sh.25,000
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

TKMR is held by these Gurus:

Premium Most recent portfolio changes are included for Premium Members only!


TKMR: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Lutwyche, PeterDirector or Senior Officer of Insider or Subsidiar 2014-12-01Sell18,000$18.4339.56view
Phillips, Peggy VanSiceDirector 2014-06-19Buy5,000$13.689.12view
Phillips, Peggy VanSiceDirector 2014-06-18Buy5,000$13.689.12view
Jewell, DonaldDirector 2014-06-16Buy2,450$14.1481.9view
Jewell, DonaldDirector 2013-08-06Buy300$6.09322.33view
Jewell, DonaldDirector 2013-08-06Buy500$6.1321.64view
Jewell, DonaldDirector 2013-08-06Buy400$6.09322.33view
Jewell, DonaldDirector 2013-08-06Buy400$6.1321.64view
Murray, Mark JosephSenior Officer 2013-04-16Buy5,000$4.6459.13view
Jewell, DonaldDirector 2013-03-12Buy1,200$4.44479.28view

Press Releases about TKMR :

    Quarterly/Annual Reports about TKMR:

    News about TKMR:

    Articles On GuruFocus.com
    Tekmira Pharmaceuticals Gets Mixed Ratings After Ebola Drug Updates Nov 11 2014 
    Ebola: Is The Cure Out There? Oct 14 2014 
    Ebola Diagnosis in U.S. Raises Pharmaceutical Stock by 20% Oct 01 2014 

    More From Other Websites
    Nasdaq stocks posting largest percentage increases Jan 26 2015
    TEKMIRA PHARMACEUTICALS CORP Files SEC form 8-K/A, Entry into a Material Definitive Agreement,... Jan 26 2015
    5 stocks to watch Jan 22 2015
    Tekmira Initiates Phase I Clinical Trial of TKM-HBV Jan 21 2015
    TEKMIRA PHARMACEUTICALS CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jan 21 2015
    Tekmira Initiates Phase I Clinical Trial of TKM-HBV Jan 21 2015
    Vical Up on Deal with AnGes to Develop Ebola Treatment - Analyst Blog Jan 15 2015
    Wall Street's Wheelings And Dealings Jan 13 2015
    Chimerix tackles Ebola outbreak Jan 13 2015
    TEKMIRA PHARMACEUTICALS CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Other... Jan 12 2015
    Will The Rally In Tekmira Pharmaceuticals Hold? Jan 12 2015
    Tekmira Purchases OnCore Biopharma To Find Hep B Cure Jan 12 2015
    Is the Merger a Great Deal for Tekmira Shareholders? Jan 12 2015
    Fresh round of M&A sweeps pharma sector Jan 12 2015
    Tekmira teams up with OnCore to focus on hepatitis B cure Jan 12 2015
    Tekmira teams up with OnCore to focus on hepatitis B cure Jan 12 2015
    Tekmira Pharmaceuticals (TKMR) Stock Soars After OnCore Biopharma Acquisition Announcement Jan 12 2015
    Morning Movers: Tiffany Tumbles as Sales Disappoint; Lululemon Jumps Jan 12 2015
    Tekmira Pharmaceuticals Soars 50% Following OnCore Biopharma Merger Jan 12 2015
    Canada's Tekmira to buy US-based OnCore Biopharma, focus on HBV treatment Jan 11 2015

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK